献血者服用药物与输血安全研究进展

doi:10.19803/j.1672-8629.2020.04.12

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (4): 249-252.
DOI: 10.19803/j.1672-8629.2020.04.12

献血者服用药物与输血安全研究进展

沈俊, 吴秋惠, 陈燕华, 彭婕^*

南京鼓楼医院,江苏南京 210008

收稿日期:2019-08-29 修回日期:2020-06-28 出版日期:2020-04-15 发布日期:2020-04-10
通讯作者: ^*彭婕,女,硕士,副主任药师,医院药学与药事管理。E-mail：361128463@qq.com
作者简介:沈俊,男,本科,药师,医院药学。

Drug Use and Transfusion Safety of Blood Donors

SHEN Jun, WU Qiuhui, CHEN Yanhua, PENG Jie^*

Nanjing Drum Tower Hospital, Nanjing Jiangsu 210008, China

Received:2019-08-29 Revised:2020-06-28 Online:2020-04-15 Published:2020-04-10

摘要/Abstract

摘要： 目的提高血液制品的安全性,制定使用药物献血者的推迟时间及管理措施,为输血安全提供参考。方法根据药物药效学和药代动力学特性以及国内外文献,提出服用药物献血者的延迟期以及管理办法。结果及结论 建议为12岁以下儿童制定特殊的血液制品。经过药物延迟期为药峰时间以及5个血浆消除半衰期（T_max + 5T_1/2）,献血者血浆中所含的药物会达到低于3%治疗浓度范围。对于使用致畸的药物、影响血小板功能的药物和基因毒性药物,必须长时间观察等待。对献血者进行认真面谈和信息采集是任何捐赠者健康检查的重要组成部分,建议联网系统管理患者用药记录。

关键词: 献血者, 延迟期, 输血安全, 药物

Abstract: Objective To improve the safety of blood products, set the delay period and formulate management measures for blood donors who have received medication in order to provide reference for blood transfusion safety. Methods According to the pharmacodynamics and pharmacokinetics of drugs and the literature at home and abroad, the delay period and management measures for blood donors who have taken drugs were proposed. Results & ConclusionIt is recommended that special blood products be developed for children under 12 years old. After the drug delay period of peak time and 5 plasma elimination half-lives (T_max+5 t_1/2), the drug content in the donor’s plasma will be less than 3% of the treatment concentration. Donors who use teratogenic drugs, genotoxic drugs and drugs that affect platelet function have to be observed and asked to wait for a long time. Serious interviews and information collection of blood donors are an important part of health check-up. It is recommended that a network system be used to keep patients’ medication records.

Key words: blood donors, delay period, transfusion safety, drug

中图分类号:

R457.1

沈俊, 吴秋惠, 陈燕华, 彭婕. 献血者服用药物与输血安全研究进展[J]. 中国药物警戒, 2020, 17(4): 249-252.

SHEN Jun, WU Qiuhui, CHEN Yanhua, PENG Jie. Drug Use and Transfusion Safety of Blood Donors[J]. Chinese Journal of Pharmacovigilance, 2020, 17(4): 249-252.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.2020.04.12

https://zgywjj.magtechjournal.com/CN/Y2020/V17/I4/249

参考文献

[1] 李健. 献血者服用药物与临床用血安全[J].中国输血杂志,2008,21(6):471-473.
[2] 何毅,安娜,吕鹤年.献血者血液中的药物与输血安全[J].华西药学杂志,2001,16(1):44-45.
[3] Sharon R, Kidroni G, Michel J.Presence of aspirin in blood units[J].Vox Sang,1980,38(2):284-287.
[4] Mahnovski V, Cheng M, Lipsey A,et al.Drugs in blood donors[J].Clin Chem,1987,33(1):189.
[5] Melanson SEF,Stowell CP,Flood JG,et al.Does blood donor historyaccurately reflect the use of prescription medications? A comparisonof donor history and serum toxicologic analysis[J]. Transfusion,2006,46(8):1402-1407.
[6] Christian DK Becker,Dirk O,Stichtenoth MGW, Michael G.Wichmann,et al. Blood Donors on Medication- an Approach toMinimize Drug Burden for Recipients of Blood Products and toLimit Deferral of Donors[J].Transfus Med Hemother,2009,36(2):107-113.
[7] Stichtenoth DO,Deicher HR,Fr lich JC. Blood donors onmedication,Are deferral periods necessary?[J].Eur J ClinPharmacol,2001,57(6-7):433-440.
[8] Bjerrum L,Andersen M,Petersen G.Exposure to potential druginteractions in primary health care[J].Scand J Prim Health Care,2003,21(3):153-158.
[9] Farrales FB.Stevenson AR.Bayer WL.Causes of Disqualificationin a Volunteer Blood Donor Population[J].Transfusion,1977,17(6):598-601.
[10] Fracasso C,Guiso G, Confalonieri S,et al.Depletion and time-course of recovery of brain serotonin after repeated subcutaneousdexfenfluramine in the mouse. A comparison with the rat[J].Neuropharmacology,1995,34(12):1653-1659.[11] Ferner RE,Dunstan JA, Chaplin S.Drugs in donated blood[J].Lancet,1989,2(8):93-94.
[12] Menth-Meier SE,Imoberdorf R,Regli B,et al.Determination ofplasma volume by indocyanine green-validation of the methodand use in patients after cardiopulmonary bypass[J].IntensiveCare Med,2001,27(5):925-929.
[13] Retzlaff JA,Tauxe WN, Kiely JM,et al.Erythrocyte volume,plasma volume, and lean body mass in adult men and women[J].Blood,1969,33(5):649-661.
[14] Schaefer C,Hannemann D,Meister R,et al.Vitamin K antagonistsand pregnancy outcome. A multi-centre prospective study[J].Thromb Haemost,2006,95(6):949-957.
[15] Ahrens I, Schwarz M, Peter K,et al.Therapeutic Inhibitors ofPlatelet Aggregation ?from Aspirin to Integrin Blockersf[J].Transfus Med Hemother,2007,34(1):44-54.
[16] Patrono C, Coller B, Dalen JE,et al.Platelet-active drugs:Therelationships among dose, effectiveness, and side effects[J].Chest,2001,119(1 ):39-63.
[17] Serebruany VL.Selective serotonin reuptake inhibitors andincreased bleeding risk: are we missing something?[J].Am JMed,2006,119(1):113-116.
[18] Yuan Y, Tsoi K, Hunt R,et al.Selective serotonin reuptake inhibitorsand risk of upper GI bleeding: confusion or confunding?[J].Am JMed ,2006,119(9):719-727.
[19] Ferner RE, Dunstan JA, Chaplin S,et al.Drugs in donated blood[J].Lancet. 1989,8(2):93-94.
[20] Kroes R,Renwick AG, Cheeseman M,et al.Structure-basedthresholds of toxicological concern (TTC): guidance for applicationto substances present at low levels in the diet[J]. Food ChemToxicol,2004,42(1):65-83.
[21] Werner B, Bodin L.Growth from birth to age 19 for childrenin Sweden born in 1981: descriptive values[J]. Acta Paediartica,2006,95(5):600-613.
[22] Michel J, Sharon R.Non-haemolytic adverse reaction aftertransfusion of a blood unit containing penicillin[J]. BMJ 1980,280(2):152-153.
[23] Sharon R, I Frutkoff, G Kidroni,et al. Applicability and significanceof salicylate screening in sera of voluntary blood donors: evaluationof two analytical methods[J].J Clin Pathol,1982,35(1): 59-62.
[24] Sharon R,Menczel J, Kidroni G.Incidence of acetaminophen indonated blood[J].Vox Sang,1982,43(3):138-141.
[25] 侯永芳,宋海波,刘红亮,等. 基于中国医院药物警戒系统开展主动监测的实践与探讨[J].中国药物警戒,2019,16(4):212-214.

献血者服用药物与输血安全研究进展

Drug Use and Transfusion Safety of Blood Donors

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	史彦蕾, 张冰, 王雨, 许卓欣, 田敏, 孟敏, 萨日娜. PDK4调控“内质网-线粒体对话”关联阿霉素心脏毒性研究进展[J]. 中国药物警戒, 2025, 22(8): 863-868.
[2]	蔡海丽, 张晓朦, 刘亚迪, 陈莉娟, 王雨, 张冰. 基于铁死亡探讨中药防治蒽环类药物心脏毒性的机制[J]. 中国药物警戒, 2025, 22(8): 876-882.
[3]	申晨, 周娴, 刘建平. 中草药-药物相互作用数据库的建立与评价方法探讨[J]. 中国药物警戒, 2025, 22(8): 902-908.
[4]	梁洁. 172例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2025, 22(8): 928-932.
[5]	雷建林, 王娜, 王文筝, 王岩. 复方妥英麻黄茶碱片致苯妥英钠中毒1例分析[J]. 中国药物警戒, 2025, 22(7): 819-822.
[6]	沈璐, 刘翠丽, 王轶, 郝明强, 王亚丽, 朱会卷, 吴晨, 杨洋. 细胞和基因治疗产品开展精准药物警戒的思考[J]. 中国药物警戒, 2025, 22(6): 633-639.
[7]	孙钟慧, 刘英纯, 董琪, 张倩, 杨静. 硫酸羟氯喹片致药物超敏反应综合征1例分析[J]. 中国药物警戒, 2025, 22(6): 689-692.
[8]	叶玲, 刘晓英, 党雪菲, 李雪莲, 李纲. 晚期乳腺癌脑转移药物研究进展[J]. 中国药物警戒, 2025, 22(6): 714-720.
[9]	孙小蕊, 赵宁, 张陆勇, 江振洲, 王欣之. 自身免疫性疾病药物相关肝损伤研究进展[J]. 中国药物警戒, 2025, 22(5): 523-527.
[10]	曹卫平, 张世超, 倪霞, 谢冰, 王欣之, 邢孟韬. 妊娠期常用药物肝损伤研究进展[J]. 中国药物警戒, 2025, 22(5): 528-531.
[11]	陈清钰, 江振洲, 张陆勇. 固有型药物性肝损伤中肝实质细胞的适应性反应研究进展[J]. 中国药物警戒, 2025, 22(5): 532-538.
[12]	刘维婷, 魏巍, 杨彦彪. 华法林钠片与迈之灵片联用致国际标准化比值异常升高1例分析[J]. 中国药物警戒, 2025, 22(5): 586-588.
[13]	闫彩瑛, 覃淋英, 徐瑶青, 王欣格, 柴囡楠, 成龙. 降尿酸药物研究进展[J]. 中国药物警戒, 2025, 22(5): 592-595.
[14]	王佳庆, 汪祺, 刘彤彤, 张冬婕, 陈启, 梅升辉, 宁霄. 高效液相色谱质谱联用法测定血浆中利奈唑胺浓度[J]. 中国药物警戒, 2025, 22(4): 377-380.
[15]	陈欢, 梁俊, 赵伟, 夏清荣. 非典型抗精神病药物致肝损伤的临床特征及危险因素分析[J]. 中国药物警戒, 2025, 22(4): 410-414.